---
schema_version: "secwatch.filing_event.v1"
accession: "0001683168-24-003796"
form_type: "8-K"
ticker: "PMCB"
cik: "0001157075"
company_name: "PharmaCyte Biotech, Inc."
filed_at: "2024-05-23T23:59:59+00:00"
generated_at: "2026-06-01T09:03:57.315015+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# PharmaCyte invests $7M in MyMD for convertible preferred stock and warrants

## Summary
- Invests $7M for Series G Convertible Preferred Stock convertible into 3,854,626 MyMD common shares at $1.816 per share.
- Also receives warrants to purchase up to 3,854,626 MyMD common shares (5-year and 18-month terms) at $1.816 per share.
- Gets right to nominate one board member while owning >20% of MyMD common stock on as-converted basis.
- MyMD filed Certificate of Designations for Series G Preferred with 10% annual dividend, compounded monthly.
- MyMD is a clinical-stage biopharma with Phase 2 data in sarcopenia (MYMD-1) and advancing toward FDA discussions.

## SEC filing metadata
- accession: 0001683168-24-003796
- form_type: 8-K
- ticker: PMCB
- cik: 0001157075
- company_name: PharmaCyte Biotech, Inc.
- filed_at: 2024-05-23T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 1.01, 2.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1157075/000168316824003796/0001683168-24-003796-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1157075/000168316824003796/pharmacyte_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001683168-24-003796
- JSON: https://secwatch.observer/filing/0001683168-24-003796.json
- Plain text: https://secwatch.observer/filing/0001683168-24-003796.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.